2024年12月24日 · BIRC3 (Baculoviral IAP Repeat Containing 3) is a Protein Coding gene. Diseases associated with BIRC3 include Lymphoma, Mucosa-Associated Lymphoid Type and Lymphoma, Non-Hodgkin, Familial. Among its related pathways are TNFR1 Pathway and Toll Like Receptor 7/8 (TLR7/8) Cascade.

2016年2月18日 · In this study, we uncover a unique role for BIRC3, as an IAP that is critical in GBM in response to therapy. Using the TCGA dataset of 524 unique samples, we identify BIRC3 is the only IAP...

Chronic lymphocytic leukemia (CLL) is characterized by recurrent genomic aberrations as well as gene mutations, and BIRC3 (Baculoviral IAP Repeat Containing 3, also called cIAP2) can be affected by both.

2021年7月9日 · BIRC3 is monoallelically deleted in up to 80% of chronic lymphocytic leukemia (CLL) cases harboring del (11q). In addition, truncating mutations in the remaining allele of this gene can lead...

Results: BIRC3 serves as a novel prognostic indicator for HCC patients undergoing curative resection. BIRC3 promotes HCC epithelial-mesenchymal transition (EMT), cell migration, and metastasis via upregulating MAP3K7, therefore, inducing ERK1/2 phosphorylation.

2025年2月8日 · BIRC3 induces tumor proliferation and metastasis in vitro and in vivo. BIRC3 may serve as a novel therapeutic target for liver cancer.

BIRC3 (Baculoviral IAP Repeat Containing 3) is a negative regulator of non-canonical NF-κB. Physiologically, BIRC3 (also known as cIAP2) catalyzes MAP3K14 protein ubiquitination in a manner that is dependent on the E3 ubiquitinine ligase activity of its C-terminal RING domain. MAP3K14 ubiquitination results in its proteasomal degradation. 4.

BIRC3 (cellular IAP2) and BIRC5 (survivin) are two of the eight members of the human IAPs family. This family is characterized by the presence of the baculoviral IAP repeat (BIR) domains, involved in protein-protein interactions.

2016年3月29日 · BIRC3 encodes a negative regulator of the non-canonical nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) protein. Disruption of BIRC3 is known to be restricted to CLL fludarabine-refractory patients.

BIRC3 Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 Mutation and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [